$OMER
OMEROS CORP

2016 Q1 Form 10-K Financial Statement

#000128581916000014 Filed on March 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2014 Q4 2014 Q3
Revenue $7.419M $180.0K $214.0K
YoY Change 1812.11% 6.51% 9.18%
Cost Of Revenue $327.0K $0.00
YoY Change 2872.73%
Gross Profit $7.092M $214.0K
YoY Change 1781.17%
Gross Profit Margin 95.59% 100.0%
Selling, General & Admin $11.11M $8.410M $5.570M
YoY Change 23.58% 116.2% 32.3%
% of Gross Profit 156.66% 2602.8%
Research & Development $15.43M $11.75M $11.77M
YoY Change 65.64% 15.31% 24.97%
% of Gross Profit 217.63% 5500.93%
Depreciation & Amortization $50.00K $70.00K $90.00K
YoY Change -16.67% -12.5% 28.57%
% of Gross Profit 0.71% 42.06%
Operating Expenses $26.87M $20.16M $17.35M
YoY Change 46.69% 43.24% 27.26%
Operating Profit -$19.45M -$19.98M -$17.13M
YoY Change 8.49% 43.68% 27.53%
Interest Expense $1.375M -$910.0K $944.0K
YoY Change 43.68% 51.67% 59.46%
% of Operating Profit
Other Income/Expense, Net $288.0K $180.0K -$251.0K
YoY Change 32.11% 20.0% -262.99%
Pretax Income -$20.54M -$20.71M -$18.33M
YoY Change 10.02% 1019.46% 32.16%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.54M -$20.71M -$18.33M
YoY Change 10.02% 1022.66% 32.13%
Net Earnings / Revenue -276.84% -11507.22% -8564.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$536.0K -$607.3K -$539.0K
COMMON SHARES
Basic Shares Outstanding 38.26M shares 34.08M shares 34.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.20M $6.900M $21.80M
YoY Change -81.17% -51.06% 142.22%
Cash & Equivalents $978.0K $354.0K $750.0K
Short-Term Investments $12.30M $6.500M $21.00M
Other Short-Term Assets $2.500M $120.0K $148.0K
YoY Change 2055.17% 39.53% -63.0%
Inventory $1.972M $568.0K
Prepaid Expenses $2.460M $1.195M $1.052M
Receivables $6.600M $300.0K $400.0K
Other Receivables $0.00 $68.00K $0.00
Total Short-Term Assets $24.32M $9.041M $23.36M
YoY Change -66.71% -38.98% 127.47%
LONG-TERM ASSETS
Property, Plant & Equipment $898.0K $782.0K $846.0K
YoY Change 23.52% -16.72% -11.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.00K $332.0K $408.0K
YoY Change -83.37% 232.0% 261.06%
Total Long-Term Assets $11.65M $1.793M $1.933M
YoY Change 531.44% 4.37% 10.84%
TOTAL ASSETS
Total Short-Term Assets $24.32M $9.041M $23.36M
Total Long-Term Assets $11.65M $1.793M $1.933M
Total Assets $35.97M $10.83M $25.29M
YoY Change -51.98% -34.48% 110.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.332M $4.915M $4.156M
YoY Change 15.64% 111.03% 23.65%
Accrued Expenses $12.12M $7.070M $6.250M
YoY Change 88.26% 79.26% 38.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $69.00K $6.330M $3.991M
YoY Change -99.23% 13.04% -0.7%
Total Short-Term Liabilities $17.52M $18.32M $14.40M
YoY Change -12.69% 54.26% 20.98%
LONG-TERM LIABILITIES
Long-Term Debt $49.97M $26.12M $28.55M
YoY Change 109.04% 75.35% 74.35%
Other Long-Term Liabilities $9.200M $9.100M $8.900M
YoY Change 1.1% 12.35% 17.11%
Total Long-Term Liabilities $49.97M $26.12M $28.55M
YoY Change 109.04% 75.35% 74.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.52M $18.32M $14.40M
Total Long-Term Liabilities $49.97M $26.12M $28.55M
Total Liabilities $67.49M $44.44M $42.95M
YoY Change 53.49% 65.99% 51.89%
SHAREHOLDERS EQUITY
Retained Earnings -$423.7M -$328.0M -$307.3M
YoY Change 22.2% 28.96% 21.7%
Common Stock $391.0K $342.0K $340.0K
YoY Change 3.44% 12.5% 14.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$40.74M -$42.65M -$26.59M
YoY Change
Total Liabilities & Shareholders Equity $35.97M $10.83M $25.29M
YoY Change -51.98% -34.48% 110.54%

Cashflow Statement

Concept 2016 Q1 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$20.54M -$20.71M -$18.33M
YoY Change 10.02% 1022.66% 32.13%
Depreciation, Depletion And Amortization $50.00K $70.00K $90.00K
YoY Change -16.67% -12.5% 28.57%
Cash From Operating Activities -$16.63M -$15.69M -$15.94M
YoY Change -4.85% 5130.0% 44.38%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$20.00K -$10.00K
YoY Change -66.67% -80.0%
Acquisitions
YoY Change
Other Investing Activities $14.63M $14.50M $14.90M
YoY Change -123.56% -397.74% 41.9%
Cash From Investing Activities $14.63M $14.49M $14.88M
YoY Change -123.57% -393.32% 42.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.500K
YoY Change -99.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.609M 820.0K 270.0K
YoY Change -98.01% -85.01% 1250.0%
NET CHANGE
Cash From Operating Activities -$16.63M -15.69M -15.94M
Cash From Investing Activities $14.63M 14.49M 14.88M
Cash From Financing Activities $1.609M 820.0K 270.0K
Net Change In Cash -$387.0K -380.0K -790.0K
YoY Change -135.6% -265.22% 38.6%
FREE CASH FLOW
Cash From Operating Activities -$16.63M -$15.69M -$15.94M
Capital Expenditures $0.00 -$20.00K -$10.00K
Free Cash Flow -$16.63M -$15.67M -$15.93M
YoY Change -4.85% 6429.17% 44.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9752000 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1952000 USD
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38257381 shares
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
629477368 USD
CY2015 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORP
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2015 dei Trading Symbol
TradingSymbol
OMER
CY2014Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
828000 USD
CY2015Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1108000 USD
CY2014Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
1280000 USD
CY2015Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
2973000 USD
CY2015 omer Beginning Year Of Expiry For Net Operating Loss Carryforwards
BeginningYearOfExpiryForNetOperatingLossCarryforwards
2018
CY2015Q4 omer Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2013 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.03
CY2014 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.02
CY2015 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.01
CY2015 omer Ending Year Of Expiry For Net Operating Loss Carryforwards
EndingYearOfExpiryForNetOperatingLossCarryforwards
2035
CY2015Q4 omer Long Term Debt Maturities Total Principal Payments
LongTermDebtMaturitiesTotalPrincipalPayments
50281000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due
NetOperatingLeasesFutureMinimumPaymentsDue
53354000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due Current
NetOperatingLeasesFutureMinimumPaymentsDueCurrent
3424000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due In Five Years
NetOperatingLeasesFutureMinimumPaymentsDueInFiveYears
4450000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due In Four Years
NetOperatingLeasesFutureMinimumPaymentsDueInFourYears
4350000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due In Three Years
NetOperatingLeasesFutureMinimumPaymentsDueInThreeYears
4259000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due In Two Years
NetOperatingLeasesFutureMinimumPaymentsDueInTwoYears
3608000 USD
CY2015Q4 omer Net Operating Leases Future Minimum Payments Due Thereafter
NetOperatingLeasesFutureMinimumPaymentsDueThereafter
33263000 USD
CY2015Q4 omer Numberof Suppliers
NumberofSuppliers
1 supplier
CY2013 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
0 USD
CY2014 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
80000 USD
CY2015 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
0 USD
CY2013Q4 omer Sales Agreement Average Share Price
SalesAgreementAverageSharePrice
13.29
CY2013 omer Sales Agreement Net Proceeds
SalesAgreementNetProceeds
4868000 USD
CY2014 omer Sales Agreement Net Proceeds
SalesAgreementNetProceeds
68000 USD
CY2015 omer Sales Agreement Net Proceeds
SalesAgreementNetProceeds
1436000 USD
CY2013Q4 omer Sales Agreement Numberof Shares Sold During Period
SalesAgreementNumberofSharesSoldDuringPeriod
374000 shares
CY2015Q4 omer Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber
2092871 shares
CY2015 omer Warrant Expiration Date
WarrantExpirationDate
2022-02-02
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4915000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6428000 USD
CY2014Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 USD
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
6208000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7070000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2400000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2228000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2432000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
285050000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
376528000 USD
CY2013 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
41000 USD
CY2014 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
863000 USD
CY2015 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6252000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8918000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9581000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
41000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
863000 USD
CY2015 us-gaap Advertising Expense
AdvertisingExpense
885000 USD
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7578319 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8915904 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9059485 shares
CY2014Q4 us-gaap Assets
Assets
10834000 USD
CY2015Q4 us-gaap Assets
Assets
48995000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
9041000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
37146000 USD
CY2014Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
6532000 USD
CY2015Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
26898000 USD
CY2013 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2014 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
200000 USD
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
137000 USD
CY2014Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
230000 USD
CY2015Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
367000 USD
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
185000 USD
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
281000 USD
CY2014Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
52000 USD
CY2015Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
98000 USD
CY2014Q4 us-gaap Cash
Cash
354000 USD
CY2015Q4 us-gaap Cash
Cash
1400000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1520000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1384000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
354000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1365000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-136000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1030000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1011000 USD
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
28300000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2009Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.25
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
749250 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38040891 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34185464 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38040891 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
342000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
380000 USD
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
749250 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10784472 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34185464 shares
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39796000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73673000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75096000 USD
CY2013 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1041000 USD
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
436000 USD
CY2015Q4 us-gaap Deferred Discounts Finance Charges And Interest Included In Receivables
DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
191000 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
9050000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
9207000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
108640000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
139054000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
88399000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
110092000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
100000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
30600000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2084000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2744000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9569000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14758000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5511000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8136000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
3077000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
3324000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
108640000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
139054000 USD
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
302000 USD
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
317000 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
209000 USD
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.35
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.22
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.36
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.41
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.02
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.05
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.04
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.05
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2421000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2590000 USD
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12900000 USD
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M13D
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-41000 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-863000 USD
CY2013 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
12500000 USD
CY2014 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2015 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2013 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1315000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15819000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22601000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35327000 USD
CY2014Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
324000 USD
CY2015Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
136000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1169000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5459000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4195000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-970000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
568000 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-96000 USD
CY2013 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
3504000 USD
CY2014 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
902000 USD
CY2015 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
157000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-84000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
987000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
586000 USD
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1555000 USD
CY2014 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
13000 USD
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
6125000 USD
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
10000000 USD
CY2013 us-gaap Interest Expense
InterestExpense
2366000 USD
CY2014 us-gaap Interest Expense
InterestExpense
3470000 USD
CY2015 us-gaap Interest Expense
InterestExpense
3573000 USD
CY2013 us-gaap Interest Paid
InterestPaid
1709000 USD
CY2014 us-gaap Interest Paid
InterestPaid
2674000 USD
CY2015 us-gaap Interest Paid
InterestPaid
4236000 USD
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
568000 USD
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
221000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
568000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
472000 USD
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 USD
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
93000 USD
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
158000 USD
CY2013 us-gaap Investment Income Net
InvestmentIncomeNet
586000 USD
CY2014 us-gaap Investment Income Net
InvestmentIncomeNet
-195000 USD
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
1030000 USD
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
71000 USD
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
289000 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
492000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10834000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48995000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18315000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16253000 USD
CY2013Q4 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
12500000 USD
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6330000 USD
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
73000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
73000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
1891000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
21258000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
19432000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
7627000 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26123000 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49769000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21650000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50857000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86826000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7909000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6157000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20606000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29695000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58044000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65209000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-39796000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-16642000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-17991000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-18327000 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-20713000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-73673000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-18669000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-16680000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-19921000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-19826000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-75096000 USD
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2013 us-gaap Operating Expenses
OperatingExpenses
52116000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
15784000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
17262000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
17346000 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
20155000 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
70547000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
18318000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
19154000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
22560000 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
24715000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
84747000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-50516000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15684000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17217000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17132000 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19975000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-70008000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17930000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15967000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19301000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-18040000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-71238000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
54616000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4106000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
1262000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4450000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4350000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4259000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4188000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
33263000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
682000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
0 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
0 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
0 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
580000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
0 USD
CY2014Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
264100000 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
325900000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
589000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
681000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
219000 USD
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
68000 USD
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
173000 USD
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
502000 USD
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
738000 USD
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
1045000 USD
CY2015Q4 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
248000 USD
CY2013Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
39000 USD
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2500000 USD
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4900000 USD
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
47182000 USD
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
58849000 USD
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
91766000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
204000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
240000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1195000 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1894000 USD
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16100000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37800000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
79100000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20988000 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37754000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
79076000 USD
CY2013 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 USD
CY2014 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
12699000 USD
CY2015 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
22329000 USD
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
55295000 USD
CY2014 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
65034000 USD
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
71400000 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
662000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1868000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2859000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1400000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3010000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3383000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
951000 USD
CY2015Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
1300000 USD
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
392000 USD
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6517000 USD
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1464000 USD
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7438000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36297000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47946000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48379000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
679000 USD
CY2015Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
10679000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-328046000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-403142000 USD
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
1600000 USD
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
539000 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
245000 USD
CY2013 us-gaap Revenues
Revenues
1600000 USD
CY2014Q1 us-gaap Revenues
Revenues
100000 USD
CY2014Q2 us-gaap Revenues
Revenues
45000 USD
CY2014Q3 us-gaap Revenues
Revenues
214000 USD
CY2014Q4 us-gaap Revenues
Revenues
180000 USD
CY2014 us-gaap Revenues
Revenues
539000 USD
CY2015Q1 us-gaap Revenues
Revenues
388000 USD
CY2015Q2 us-gaap Revenues
Revenues
3187000 USD
CY2015Q3 us-gaap Revenues
Revenues
3259000 USD
CY2015Q4 us-gaap Revenues
Revenues
6675000 USD
CY2015 us-gaap Revenues
Revenues
13509000 USD
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
13264000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
6252000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
8918000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
9581000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0187
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0168
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6217364 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.61
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2900000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3900000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
127853 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.36
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
350975 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.87
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.39
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.31
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
65610000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8364469 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8310235 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.52
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.97
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
64731000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8096339 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.85
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.13
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.90
CY2013 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
40000 shares
CY2014 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
86000 shares
CY2015 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
4200 shares
CY2014Q1 us-gaap Share Price
SharePrice
11.50
CY2013Q2 us-gaap Share Price
SharePrice
4.14
CY2015Q1 us-gaap Share Price
SharePrice
20.03
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M29D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M3D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M15D
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
56757000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M26D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y0M25D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y0M0D
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3900000 shares
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3500000 shares
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3400000 shares
CY2014 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
28653 shares
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
277356 shares
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16120000 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37754000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
79076000 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
662000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1800000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1423000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-6531000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-18384000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-42654000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-26234000 USD
CY2014 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2015 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
212000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
212000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
212000 USD
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1300000 USD
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14500000 USD
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
25800000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
30400000 USD
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28560360 shares
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33234294 shares
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37560257 shares
CY2015 us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Advertising</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs, which we consider to be media and marketing materials, are expensed as incurred. We incurred $</font><font style="font-family:inherit;font-size:10pt;">885,000</font><font style="font-family:inherit;font-size:10pt;"> in advertising expense during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. We had no similar expenses during the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Major Suppliers</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use a small number of contract manufacturers to supply OMIDRIA and to produce clinical trial material which creates a concentration of risk for us. With regards to OMIDRIA, Patheon Manufacturing Services, LLC (Patheon) is completing the analytical testing required before transferring OMIDRIA commercial product, costing </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, to us. We anticipate receiving the product during the first quarter of 2016 and the product dating will allow the product to be sold through at least the third quarter of 2018. This is the final commercial supply of OMIDRIA that Patheon will be available to produce using Patheon&#8217;s facility currently approved for manufacturing OMIDRIA.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a non-exclusive agreement with Hospira Worldwide, Inc. (Hospira) for the ongoing commercial supply of OMIDRIA and we are currently completing the manufacturing process transfer, process validation and approval of Hospira as a manufacturing site for OMIDRIA. We anticipate Hospira will be able to provide OMIDRIA commercial product to us beginning in 2017.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the commercial supply of OMIDRIA currently undergoing final analytical testing at Patheon plus our OMIDRIA inventory on hand will be adequate to supply our needs of OMIDRIA until Hospira is able to supply our OMIDRIA commercial product needs.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> source of supply is utilized for OMIDRIA and generally one source for each of our product candidates, other sources are available should we need to change suppliers. We endeavor to maintain reasonable levels of drug supply for our commercial and clinical trial use. A change in suppliers, however, could cause a delay in delivery of OMIDRIA or our clinical trial material that would adversely affect our business. </font></div></div>
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. </font></div></div>
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior periods in the consolidated financial statements and the accompanying notes to conform with the current presentation, none of which impacted our net loss or working capital.</font></div></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0001285819-16-000014-index-headers.html Edgar Link pending
0001285819-16-000014-index.html Edgar Link pending
0001285819-16-000014.txt Edgar Link pending
0001285819-16-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
omer-201412_chartx20416a01.jpg Edgar Link pending
omer-20151231.xml Edgar Link completed
omer-20151231.xsd Edgar Link pending
omer-20151231x10k.htm Edgar Link pending
omer-20151231_cal.xml Edgar Link unprocessable
omer-20151231_def.xml Edgar Link unprocessable
omer-20151231_lab.xml Edgar Link unprocessable
omer-20151231_pre.xml Edgar Link unprocessable
omer-ex1042.htm Edgar Link pending
omer-ex121_ratioofearnings.htm Edgar Link pending
omer-ex231_consentofindepe.htm Edgar Link pending
omer-ex311_20151231.htm Edgar Link pending
omer-ex312_20151231.htm Edgar Link pending
omer-ex321_20151231.htm Edgar Link pending
omer-ex322_20151231.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending